Home LiteratureArticle Details
PMID: 9040028 Published · ppublish English Comparative Study Journal Article Research Support, Non-U.S. Gov't

Selective blockade of AT1 angiotensin II receptors abolishes ischemic preconditioning in isolated rabbit hearts.

Journal of molecular and cellular cardiology ·Vol. 29 ·No. 1 ·1997-01-00 ·Pages 129-39

Diaz RJ, Wilson GJ

Abstract

The aim of the present study was to assess the participation of angiotensin II receptors in the triggering mechanism of ischemic preconditioning. Isolated buffer-perfused rabbit hearts were subjected to 40 min of regional ischemia (37 degrees C) followed by 60 min of reperfusion. Ischemic preconditioning was induced with three cycles of 5-min ischemia and 10-min reperfusion given prior to the 40-min ischemic period. Infarct size and ventricular function were assessed. Ischemic preconditioning reduced infarct size to 5.2 +/- 1.2% of the area at risk (mean +/- S.E.M., P<0.001) when compared to controls (26.4 +/- 3.0%), but did not protect against ventricular dysfunction. Activation of angiotensin II receptors with angiotensin II (100 nM) also limited infarct size (9.6 +/- 2.2%, P<O.01 v control group). Inhibition of angiotensin II receptors with [Sar1, Val5, Ala8]-angiotensin II (saralasin, 1 microM) blocked the protection of ischemic preconditioning against necrosis (29.7 +/- 3.2%) while it did not increase infarct size in saralasin-treated control hearts (31.5 +/- 3.9%). Furthermore, inhibition of the AT1 subtype of the angiotensin II receptor with losartan (20 microM), but not inhibition of the AT2 subtype with PD-123,319 ditrifluoroacetate (10 microM), abolished the infarct size-limiting effect of ischemic preconditioning. We conclude that the AT1 angiotensin II receptor participates in ischemic preconditioning. Thus, in the isolated rabbit heart, activation of AT1 receptors must occur before prolonged ischemia for ischemic preconditioning to limit infarction.

MeSH Terms
Analysis of Variance Angiotensin Receptor Antagonists Animals Biphenyl Compounds/therapeutic use Coronary Circulation/drug effects Drug Evaluation, Preclinical Female Imidazoles/therapeutic use In Vitro Techniques Ischemic Preconditioning, Myocardial Losartan Male Myocardial Infarction/pathology Myocardial Reperfusion Rabbits Renin-Angiotensin System/drug effects Saralasin/therapeutic use Tetrazoles/therapeutic use Ventricular Dysfunction, Left/prevention & control
Chemicals
Angiotensin Receptor Antagonists Biphenyl Compounds Imidazoles Tetrazoles Saralasin Losartan
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Diaz R J
Division of Cardiovascular Research, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada.
Wilson G J
Article Info
Journal
Journal of molecular and cellular cardiology
Abbr.
J Mol Cell Cardiol
ISSN
0022-2828
Published
1997-01-00
Pages
129-39
Language
English
Region
England
NLM ID
0262322
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]